Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Research & Development (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Research & Development for 16 consecutive years, with $177.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development rose 29.34% year-over-year to $177.2 million, compared with a TTM value of $647.4 million through Dec 2025, up 22.98%, and an annual FY2025 reading of $607.2 million, up 20.02% over the prior year.
  • Research & Development was $177.2 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $174.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $177.2 million in Q4 2025 and bottomed at $44.7 million in Q1 2021.
  • Average Research & Development over 5 years is $105.5 million, with a median of $97.3 million recorded in 2023.
  • The sharpest move saw Research & Development soared 82.13% in 2021, then decreased 1.45% in 2023.
  • Year by year, Research & Development stood at $65.8 million in 2021, then grew by 27.26% to $83.7 million in 2022, then soared by 39.19% to $116.5 million in 2023, then grew by 17.61% to $137.0 million in 2024, then rose by 29.34% to $177.2 million in 2025.
  • Business Quant data shows Research & Development for ARWR at $177.2 million in Q4 2025, $174.7 million in Q3 2025, and $162.4 million in Q2 2025.